Literature DB >> 10672634

Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze.

J C Cole1, J M Littleton, H J Little.   

Abstract

RATIONALE: Drugs that reduce relapse in alcoholics are thought to inhibit either positive reinforcement for drinking (e.g. naltrexone) or negative reinforcement (e.g. acamprosate), and may reduce the impact of conditioned stimuli associated with previous alcohol use. We have developed a model for such conditioning by repeatedly pairing ethanol administration with plus-maze exposure. Substitution of saline for ethanol greatly increased stretched-attend postures and time in the central square, conditioned to the environment.
OBJECTIVE: To test the hypothesis that if this behaviour indicates a negative affective state caused by the expectation of ethanol, it should be inhibited by drugs that reduce negative, but not positive, reinforcement.
METHODS: The effects of naltrexone and acamprosate on alcohol-conditioned abstinence behaviour were compared.
RESULTS: Acute administration of either drug alone produced no significant effects on plus-maze behaviour in naive mice. Naltrexone had no significant effect on the alcohol-conditioned abstinence behaviour, but acamprosate reduced the incidence of stretched-attend postures.
CONCLUSIONS: The experiments replicated previous findings for alcohol/environment conditioned behaviour, and demonstrated, as predicted, that this was decreased by acamprosate but not by naltrexone. Effects of acamprosate on conditioned negative reinforcement may be the cause of this effect, but more work is required to establish the usefulness of this model in evaluation of anti-relapse drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10672634     DOI: 10.1007/s002130050009

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

Review 1.  Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action.

Authors:  Philippe De Witte; John Littleton; Philippe Parot; George Koob
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 3.  The development of acamprosate as a treatment against alcohol relapse.

Authors:  Peter R Kufahl; Lucas R Watterson; M Foster Olive
Journal:  Expert Opin Drug Discov       Date:  2014-09-26       Impact factor: 6.098

Review 4.  Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism.

Authors:  C Gianoulakis
Journal:  J Psychiatry Neurosci       Date:  2001-09       Impact factor: 6.186

Review 5.  The clinical pharmacology of acamprosate.

Authors:  Nicola J Kalk; Anne R Lingford-Hughes
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 6.  Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence.

Authors:  Barbara J Mason; Charles J Heyser
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

7.  A behavioral and pharmacological characterization of palatable diet alternation in mice.

Authors:  Catherine F Moore; Gabrielle S Schlain; Samantha Mancino; Valentina Sabino; Pietro Cottone
Journal:  Pharmacol Biochem Behav       Date:  2017-10-31       Impact factor: 3.533

8.  Acamprosate attenuates the handling induced convulsions during alcohol withdrawal in Swiss Webster mice.

Authors:  Ben Lewis; Dennis J Morrell; Justin M Farook; Ali Krazem; John M Littleton; Susan Barron
Journal:  Physiol Behav       Date:  2008-06-06

9.  The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial.

Authors:  Anders Hammarberg; Nitya Jayaram-Lindström; Olof Beck; Johan Franck; Malcolm S Reid
Journal:  Psychopharmacology (Berl)       Date:  2009-03-25       Impact factor: 4.530

10.  Development of a mouse model of ethanol addiction: naltrexone efficacy in reducing consumption but not craving.

Authors:  D J Fachin-Scheit; A Frozino Ribeiro; G Pigatto; F Oliveira Goeldner; R Boerngen de Lacerda
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.